Cardiovascular disease affects people of all ages, but stroke and heart disease are major drivers of disability and death. This page explains the burden using outcome, utilization, and cost data—from 2019 global DALYs to U.S. care patterns and delays. You’ll also see how key risk factors such as hypertension, diabetes, obesity, and smoking connect to outcomes, plus where prevention and treatment support can make a difference.
Key Takeaways
- 6.1% of the global total DALYs in 2019 were attributed to stroke—another major CVD component.
- 655,000 U.S. deaths due to heart disease in 2021—annual mortality burden.
- 160,000 U.S. deaths due to stroke in 2021—annual mortality burden.
- Cardiovascular disease costs the U.S. $1.1 trillion per year (2014)—includes direct and indirect costs.
- $207 billion in 2023 U.S. spending attributed to heart disease and stroke—estimated medical costs (direct).
- 30% of total U.S. healthcare spending is estimated to be avoidable—relevant to prevention of CVD complications.
- 38.7% of U.S. adults aged ≥20 have high blood pressure control failure (uncontrolled hypertension) in 2017–2018—percentage of hypertensive individuals not meeting control targets.
- 11.5% of U.S. adults (2017–2018) have diabetes—diabetes prevalence linked to CVD risk.
- 32.2% of U.S. adults are obese (2017–2018)—major CVD risk factor.
- In 2022, 78.9% of eligible U.S. patients received smoking cessation advice after a CVD-related encounter—quality measure.
- In 2019, the median time from symptom onset to arrival for U.S. heart attack patients was 2 hours—pre-hospital delay context.
- In 2021, the estimated number of outpatient visits for CVD in the U.S. was 336 million—utilization scale.
- In 2020, 26.8% of U.S. adults with hypertension had their blood pressure under control?—based on NHANES estimate.
- The median EMS response time for cardiac arrest in the U.S. is 8 minutes—time-to-treatment proxy.
- Neurologically favorable survival after OHCA in the U.S. was 4.6% in 2019—outcome measure.
Cardiovascular disease drives millions of deaths, massive costs, and ongoing risk factor control gaps despite prevention efforts.
Related reading
01 · Category
Risk Factors9 stats
01
38.7% of U.S. adults aged ≥20 have high blood pressure control failure (uncontrolled hypertension) in 2017–2018—percentage of hypertensive individuals not meeting control targets.[1]
02
11.5% of U.S. adults (2017–2018) have diabetes—diabetes prevalence linked to CVD risk.[1]
03
32.2% of U.S. adults are obese (2017–2018)—major CVD risk factor.[1]
04
14.1% of U.S. adults smoke cigarettes (2018)—tobacco risk factor.[1]
05
In 2021, 36.5% of U.S. adults had obesity (BMI ≥30)—risk factor for CVD.[1]
06
In 2019, 38% of adults aged ≥18 worldwide were insufficiently physically active—global CVD risk context.[2]
07
In 2019, 22% of adults worldwide were current smokers—global tobacco exposure.[2]
08
In 2019, 1.0 billion people worldwide had hypertension—global scale.[2]
09
In 2019, 8% of adults worldwide had diabetes—diabetes as CVD risk context.[2]
Interpretation
Risk Factors Interpretation
Risk factors for cardiovascular disease remain widespread, with 38.7% of U.S. adults still reporting uncontrolled hypertension in 2017 to 2018, alongside high rates of obesity (32.2% in 2017 to 2018, rising to 36.5% in 2021) and physical inactivity globally where 38% of adults worldwide were insufficiently active in 2019.
02 · Category
Epidemiology7 stats
01
6.1% of the global total DALYs in 2019 were attributed to stroke—another major CVD component.[3]
02
655,000 U.S. deaths due to heart disease in 2021—annual mortality burden.[1]
03
160,000 U.S. deaths due to stroke in 2021—annual mortality burden.[1]
04
In 2019, 1.3 million CVD-related deaths occurred in people aged 30–69 in the EU (est.)—premature mortality in OECD region.[4]
05
Stroke prevalence increased from 5.3 million in 2010 to 7.9 million in 2018 in the U.S.—trend in epidemiology.[5]
06
6.5 million U.S. adults reported having angina/other coronary heart disease symptoms in 2019–2020[6]
07
70.1% of U.S. adults with any form of cardiovascular disease (CVD) were aged 60 years or older (NHIS, 2019)[7]
Interpretation
Epidemiology Interpretation
The epidemiology picture for cardiovascular disease is dominated by ongoing burden and growth, with stroke accounting for 6.1% of global DALYs in 2019, U.S. deaths reaching 655,000 for heart disease and 160,000 for stroke in 2021, and U.S. stroke prevalence rising from 5.3 million in 2010 to 7.9 million in 2018.
03 · Category
Industry Trends6 stats
01
The global market size for cardiovascular devices was $92.3 billion in 2023—cardiovascular medtech industry scale.[8]
02
The global cardiovascular therapeutics market reached $144.6 billion in 2022—pharmaceutical market scale.[9]
03
The global heart valve market was $7.9 billion in 2023—interventional CVD devices segment.[10]
04
The global implantable cardioverter-defibrillator (ICD) market was $4.5 billion in 2023—device segment scale.[10]
05
The global structural heart disease market was $8.7 billion in 2023—interventional CVD segment growth.[11]
06
The global cardiac resynchronization therapy (CRT) market was valued at $3.2 billion in 2023—device subsegment scale.[12]
Interpretation
Industry Trends Interpretation
The cardiovascular medtech and related markets are expanding across both devices and therapies, with cardiovascular devices reaching $92.3 billion in 2023 and cardiovascular therapeutics hitting $144.6 billion in 2022, underscoring strong industry momentum for CVD innovation.
More related reading
04 · Category
Cost Analysis5 stats
01
Cardiovascular disease costs the U.S. $1.1 trillion per year (2014)—includes direct and indirect costs.[7]
02
$207 billion in 2023 U.S. spending attributed to heart disease and stroke—estimated medical costs (direct).[7]
03
30% of total U.S. healthcare spending is estimated to be avoidable—relevant to prevention of CVD complications.[6]
04
6.1% of total U.S. healthcare spending was attributable to cardiovascular disease in 2022 (direct + indirect modeled share)[7]
05
$7.6 billion annual direct medical costs in the U.S. associated with atrial fibrillation (2019 estimate, updated to 2022 dollars in study)[13]
Interpretation
Cost Analysis Interpretation
Cardiovascular disease drives enormous and largely preventable costs, with $1.1 trillion per year in the US and 30% of total healthcare spending estimated to be avoidable, so reducing CVD complications could meaningfully reduce this $1.1 trillion burden.
05 · Category
Service Delivery3 stats
01
In 2022, 78.9% of eligible U.S. patients received smoking cessation advice after a CVD-related encounter—quality measure.[14]
02
In 2019, the median time from symptom onset to arrival for U.S. heart attack patients was 2 hours—pre-hospital delay context.[1]
03
In 2021, the estimated number of outpatient visits for CVD in the U.S. was 336 million—utilization scale.[15]
Interpretation
Service Delivery Interpretation
From 2019 to 2022, service delivery for cardiovascular disease shows a mixed picture with a median heart attack pre-hospital delay of 2 hours, while 78.9% of eligible U.S. patients received smoking cessation advice after a CVD encounter and outpatient utilization reached 336 million visits in 2021.
06 · Category
Overview11 stats
01
In 2020, 26.8% of U.S. adults with hypertension had their blood pressure under control?—based on NHANES estimate.[1]
02
The median EMS response time for cardiac arrest in the U.S. is 8 minutes—time-to-treatment proxy.[7]
03
Neurologically favorable survival after OHCA in the U.S. was 4.6% in 2019—outcome measure.[1]
04
48.2% of U.S. adults with hypertension had their blood pressure under control (2017–2020)[1]
05
37.0% of U.S. adults with hypertension had controlled blood pressure in 2017–2018 (NHANES)[1]
06
79.0% of U.S. adults with hypertension were overweight or obese (2017–2018 NHANES)[1]
07
$14.3 billion global transcatheter aortic valve replacement (TAVR) market value in 2022 (therapies/bioprosthetic valves segment, estimate)[16]
08
3.0% year-over-year growth rate in global cardiovascular imaging market revenue in 2023[17]
09
Global percutaneous coronary intervention (PCI) devices market exceeded $25 billion in 2023 (stents/catheters segment, industry estimate)[12]
10
14.6 million U.S. adults were treated for coronary heart disease in 2021 (AHA statistics based on survey/modeling)[7]
11
25.0% of U.S. Medicare beneficiaries with heart failure were readmitted within 30 days (2019 cohort measure)[18]
Interpretation
Industry Overview Interpretation
From an industry overview perspective, only 26.8% of U.S. adults with hypertension had controlled blood pressure in 2020, showing a persistent control gap despite 48.2% having control over 2017 to 2020 and underscoring the continued need for effective hypertension management solutions.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Ryan Townsend. (2026, February 13). Cardiovascular Disease Statistics. Gitnux. https://gitnux.org/cardiovascular-disease-statistics
MLA
Ryan Townsend. "Cardiovascular Disease Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/cardiovascular-disease-statistics.
Chicago
Ryan Townsend. 2026. "Cardiovascular Disease Statistics." Gitnux. https://gitnux.org/cardiovascular-disease-statistics.
Sources & references
18 sources cited across this report